Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors

Thursday, January 31, 2008 General News J E 4
SEATTLE, Jan. 31 Koronis Pharmaceuticals, Inc., abiotechnology company focused on the development of antiviral therapeutics,today announced the appointment of Daniel H. Petree and George R. Painter,Ph.D. to the Company's board of directors.

Mr. Petree is a founder and member of P2 Partners, LLC, a boutiqueinvestment bank specializing in life science companies. Prior to forming P2Partners, Mr. Petree held various executive management positions in the lifesciences industry, including President and Chief Operating Officer of AxysPharmaceuticals and Vice President of Business Development at TSI Corporation.He also served as Vice President in the Health Care Group at the investmentbank Montgomery Securities. Mr. Petree currently serves as Director forCypress BioSciences.

Dr. Painter is president and chief executive officer of Chimerix, abiotechnology company developing orally available antiviral therapeutics.Prior to that, he served as Executive Vice President, Research andDevelopment, at Triangle Pharmaceuticals where he was a member of the foundingmanagement team. Dr. Painter has also held positions at Burroughs WellcomeCo., and Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over forty-fivepatents, six of which have led to approved commercially available drugs orcombinations of drugs for the treatment of HIV and hepatitis B. Dr. Painterearned a B.S. in chemistry, an M.S. in physical organic chemistry and a synthetic chemistry from Emory University.

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology companydeveloping anti-viral therapeutics based on a novel mechanism, Viral DecayAcceleration (VDA). The Company's lead product candidate, KP-1461 for thetreatment of human immunodeficiency virus (HIV), is currently being evaluatedin a Phase 2 trial. In addition to KP-1461, the Company has products indevelopment for the treatment of hepatitis C and RSV. For more information onKoronis, please visit Contact: Julie Rathbun Rathbun Communications, Inc. Tel : (206) 769-9219

SOURCE Koronis Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
ATS Medical Provides Update on First Generation Ti...
CombiMatrix and Clarient Collaborate to Market, Se...